Charnock-Jones D S, Sharkey A M, Fenwick P, Smith S K
Department of Obstetrics and Gynaecology, University of Cambridge, Rosie Maternity Hospital, UK.
J Reprod Fertil. 1994 Jul;101(2):421-6. doi: 10.1530/jrf.0.1010421.
Maternal endometrial leukaemia inhibitory factor (LIF) is required for successful implantation in mice. Mice with homozygous deletions in this gene fail to support implantation. The localization of immunoreactive LIF and the concentration of the mRNA encoding human LIF in normal endometrium during the menstrual cycle were investigated. The amount of RNA was low or undetectable in the proliferative phase but increased by approximately six times in the mid- to late secretory phase. The protein can only be detected by immunocytochemistry in glandular epithelium in the mid- or late secretory phase. To investigate the possible target for the endometrial LIF, we undertook reverse transcription-PCR analysis of early human embryos to determine whether they contain the mRNA encoding the LIF receptor. This study indicated that at the time of implantation in humans, the maternal endometrium produces LIF and that the blastocyst expresses LIF receptor mRNA and therefore may be capable of responding to this signal.
母体子宫内膜白血病抑制因子(LIF)对小鼠成功着床至关重要。该基因纯合缺失的小鼠无法支持着床。研究了月经周期中正常子宫内膜中免疫反应性LIF的定位以及编码人LIF的mRNA浓度。增殖期RNA量低或无法检测到,但在分泌中期至晚期增加了约六倍。该蛋白仅在分泌中期或晚期的腺上皮中通过免疫细胞化学检测到。为了研究子宫内膜LIF的可能靶标,我们对早期人类胚胎进行了逆转录-聚合酶链反应分析,以确定它们是否含有编码LIF受体的mRNA。这项研究表明,在人类着床时,母体子宫内膜产生LIF,而囊胚表达LIF受体mRNA,因此可能能够对该信号作出反应。